Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | STAMPEDE: local radiotherapy improves survival in metastatic prostate cancer

Chris Parker • 21 Oct 2018
ESMO 2018
Genitourinary Cancer Prostate Cancer
STAMPEDE

Update on the survival results from the STAMPEDE trial (NCT00268476), investigating radiotherapy to the primary tumour for men with newly-diagnosed metastatic prostate cancer. Presented by Chris Parker, BM, BChir, MD, FRCR, MRCP from the Royal Marsden NHS Foundation Trust, London, UK, at the prostate cancer press briefing at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Results showed that by treating the primary tumour with radiotherapy, there was a significant survival benefit in men with low metastatic burden.

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals